...
首页> 外文期刊>Journal of diabetes and its complications >Geographic variation in pharmacotherapy decisions for U.S. medicare enrollees with diabetes
【24h】

Geographic variation in pharmacotherapy decisions for U.S. medicare enrollees with diabetes

机译:美国医疗保险糖尿病患者药物治疗决策的地域差异

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Prescription rates for diabetic drugs vary considerably across the United States for Medicare beneficiaries. The goal of this study was to determine if non-clinical factors (patient race, ethnicity, gender, income) are associated with regional variation in pharmacotherapy decisions for diabetic patients enrolled in Medicare. Methods: We performed a spatially-weighted, linear regression analysis of the entire diabetic population enrolled in Medicare Parts A, B, and D for the years 2006 through 2009. Our outcomes of interest were the percentage of diabetic patients being treated with metformin, a sulfonylurea, a thiazolidinedione, or insulin within a hospital referral region (HRR). Results: Prescription rates for metformin, sulfonylureas, thiazolidinediones, and insulin varied more than two-fold between hospital referral region. Metformin prescription rates were increased in western states while prescription rates for sulfonylureas and insulins were highest in the South and Midwest. In contrast with these other diabetic drug classes, members of the thiazolidinedione drug class were prescribed more frequently in the Central United States (Great Plains, Colorado Rockies, Northern Texas, Oklahoma). Prescription rates for each drug class were increased in hospital referral regions with a lower household income. Referral regions with larger African American populations were associated with higher prescription rates for insulin (p < 0.001) and lower prescription rates for metformin (p < 0.001). Gender and Hispanic ethnicity were not associated with regional variation in prescription rates for the four major diabetic drug classes. Conclusions: Geographic differences exist in the management of type 2 diabetes for Medicare enrollees. Prescription patterns were associated with household income and African American race. Further studies are necessary to identify local, unidentified factors that might be influencing provider management styles.
机译:目标:在美国,医疗保险受益人的糖尿病药物处方率差异很大。这项研究的目的是确定在参加Medicare的糖尿病患者中,非临床因素(患者种族,种族,性别,收入)是否与药物治疗决策的区域差异有关。方法:我们对2006年至2009年参加Medicare A,B和D部分的整个糖尿病人群进行了空间加权的线性回归分析。我们感兴趣的结果是接受二甲双胍治疗的糖尿病患者的百分比医院转诊区域(HRR)中的磺酰脲类,噻唑烷二酮或胰岛素。结果:在医院转诊区域之间,二甲双胍,磺酰脲类,噻唑烷二酮和胰岛素的处方率变化超过两倍。西部各州的二甲双胍处方率增加,而南部和中西部的磺酰脲类和胰岛素处方率最高。与其他糖尿病药物类别相反,在美国中部(大平原,科罗拉多洛矶山脉,德克萨斯州北部,俄克拉荷马州)更频繁地开具噻唑烷二酮类药物。家庭收入较低的医院转诊地区,每种药物的处方率均增加。非裔美国人人口较多的转诊地区与较高的胰岛素处方率(p <0.001)和较低的二甲双胍处方率(p <0.001)相关。性别和西班牙裔种族与四种主要糖尿病药物类别的处方率区域差异无关。结论:Medicare参加者在2型糖尿病的管理上存在地区差异。处方模式与家庭收入和非裔美国人种族有关。有必要进行进一步的研究以确定可能影响提供商管理方式的本地未识别因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号